

# 2019 Patient Access Philosophy Report

Data as of Q2 '19 Earnings

## Making Our Medicines Available to Those Who Will Benefit from Them Most

Patients often have trouble accessing the medicines their doctors prescribe. At Alnylam, we believe that is unacceptable. Before our first medicine launched, we made a commitment to ensure our medicines get to those who will benefit from them. Our Patient Access Philosophy serves as our compass for fulfilling that promise – putting patients first, continuing our focus on innovation, and being accountable to patients and their families. We are proud to share how we are living those values.

- **HELP PATIENTS**
- **DELIVER VALUE**
- **BE PROACTIVE**

## Help Patients to Access Alnylam Medicines



**>500**

Patients worldwide receiving commercial ONPATTRO® (patisiran)



**6**

European countries<sup>2</sup> where patients have broad access to ONPATTRO, if prescribed



**80%**

of U.S. patients have zero cost-share for ONPATTRO<sup>1</sup>



**>300**

Patients around the world have received or are receiving ONPATTRO via compassionate access



**355**

Infusion-ready sites in U.S.



**>15,000**

Samples submitted to Alnylam Act® – a free genetic testing and counseling program in North America



**85%**

of patients engaged in Alnylam Assist™ ask to have a visit from a Patient Education Liaison



**~100**

Patients actively enrolled in U.S. commercial copay program

## Deliver Value to Payers and Physicians



**>10**

Signed Value Based Agreements (VBA)



**0**

Price increases



**98%**

of U.S. lives with confirmed access to ONPATTRO across commercial, Medicare, Medicaid and other government payer categories

<sup>1</sup> Includes patients utilizing commercial co-pay, Managed Medicare and Medicare FFS plus supplement

<sup>2</sup> European Union plus European Economic Area

## Be Proactive and Accountable



**5**

Alnylam-sponsored clinical trials studying ATTR amyloidosis ongoing or planned by end of 2019



**4.8 out of 5**

Recent satisfaction score from patients on Alnylam Assist



**~6 years**

Longest duration of treatment with ONPATTRO



**55**

Patient education events hosted by Alnylam in the U.S. and EU since launch



**366**

Engagements with U.S. patients and their families since launch through Alnylam Assist<sup>1</sup>



**24**

Grants provided to 15 ATTR patient organizations globally since launch



**>370 million**

People live in other geographies – including Canada, Japan and Latin America, where Alnylam is actively working to make ONPATTRO commercially available

## Ensuring Access and Delivering Value

Alnylam's Patient Access Philosophy is an important first step for patients to gain access to the medicines they need. We have seen this work well for our ONPATTRO patients, and we will apply this philosophy across our entire portfolio. As we grow our global footprint, we will continue to price our medicines responsibly and consistently with the value delivered and in consideration of the rare diseases they treat. We will not make arbitrary price increases. We view ourselves as a citizen of the global health community and commit ourselves to innovative solutions for patient access. We remain steadfast in our commitment to patients and dedicated to developing investigational therapies to help people with serious and life-threatening diseases.



“We have taken a proactive approach to helping patients gain access to our medications, and we are proud to see that these efforts are making a difference. There is still more to do, and we will continue to work with healthcare providers, families and caregivers, insurance companies and other payers to help patients with rare diseases live healthier lives.”

John Maraganore, Alnylam CEO

<sup>1</sup> As of August 10, 2019